[Long-term prognosis in patients with acute non-ST-segment elevation myocardial infarction depending on dynamics of tissue myocardial dopplerography]
Insights
Persistent diffuse changes in myocardial tissue dopplerography (MTD) after non-ST elevation acute myocardial infarction (AMI) indicate a poor long-term prognosis, increasing the risk of cardiac failure and silent left ventricular dysfunction.
Area of Science:
- Cardiology
- Echocardiography
- Myocardial Infarction
Background:
- Non-ST elevation acute myocardial infarction (NSTEMI) requires understanding long-term prognostic indicators.
- Myocardial tissue dopplerography (MTD) assesses myocardial function and can reveal subtle changes post-infarction.
Purpose of the Study:
- To investigate the long-term prognosis of patients with NSTEMI based on changes in MTD during treatment.
- To correlate MTD patterns with the development of congestive cardiac failure (CCF) and asymptomatic left ventricular (LV) dysfunction.
Main Methods:
- Echocardiography with MTD was performed on 88 NSTEMI patients and 34 healthy controls.
- MTD measurements of systolic and diastolic velocities were taken at multiple LV wall levels.
- Patients were followed for 10-18 months post-discharge to assess long-term outcomes.
Main Results:
- NSTEMI patients were categorized into subgroups based on MTD patterns: asymmetric decrease (19.3%), diffuse decline (69.3%), and no change (11.4%).
- Treatment led to a reduction in diffuse MTD decline (35.3%) and an increase in asymmetric MTD (42%) and unchanged MTD (22.7%).
- A persistent diffuse decrease in MTD was associated with a significantly higher rate of CCF and asymptomatic LV dysfunction.
Conclusions:
- Treatment for NSTEMI can improve MTD patterns, shifting from diffuse to asymmetric or normalized patterns.
- The persistence of diffuse MTD changes post-treatment is a significant unfavorable prognostic factor for long-term cardiac health.
- MTD is a valuable tool for predicting long-term outcomes in NSTEMI patients.
Aim:
To study long-term prognosis in patients with non-ST elevation acute myocardial infarction (AMI) with reference to changes in myocardial tissue dopplerography (MTD) in the course of treatment.
Material And Methods:
MTD echocardiography was conducted in 88 non-ST elevation AMI (mean age 58.0-9.8 years) and 34 healthy volunteers (mean age 58.0 +/- 9.8 years). Measurements were made of the velocity of systolic, early and late diastolic peaks at 4 levels of interventricular septum, anterior, lateral and inferior walls of the left ventricle (LV). MTD was repeated before the discharge from hospital. The patients were followed up for 10-18 months after the discharge.
Results:
By MTD results the patients were divided into 3 subgroups: 1--an asymmetric decrease of MTD values--17(19.3%) patients who had a 20% reduction of the systolic and early diastolic peak velocity compared to healthy controls on one or two adjacent LV walls; subgroup 2--a diffuse decline of MTD values--61 (69.3%) patients. Their velocity of systolic and early diastolic peaks was subnormal on all the walls, all levels of estimation; subgroup 3--10 (11.4%) patients without MTD changes. These proportions changed in the course of treatment: the number of patients with a diffuse decrease of MTD values reduced to 31 (35.3%), the number of patients with an asymmetric MTD decrease rose to 37 (42%), and with unchanged MTD rose to 20 (22.7%) patients. The rate of development of congestive cardiac failure (CCF) and asymptomatic LV dysfunction in the long-term period was significantly higher in the subgroup with retained diffuse decrease of MTD values.
Conclusion:
The treatment of non-ST elevation AMI reduces the number of patients with a diffuse decrease of MTD values and elevates the number of patients with asymmetric decrease of MTD and unchanged MTD. Persistence of MTD diffuse changes is an unfavourable prognostic factor in relation to CCF and LV silent dysfunction.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy II: Dilated Cardiomyopathy


